Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies
Authors
Keywords
-
Journal
Antibiotics-Basel
Volume 10, Issue 10, Pages 1226
Publisher
MDPI AG
Online
2021-10-11
DOI
10.3390/antibiotics10101226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
- (2021) Qiuxia Lin et al. BMC MICROBIOLOGY
- In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy
- (2021) Stefano Stracquadanio et al. Journal of Global Antimicrobial Resistance
- Advances in the Microbiology of Stenotrophomonas maltophilia
- (2021) Joanna S. Brooke CLINICAL MICROBIOLOGY REVIEWS
- Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy
- (2021) Shauna Jacobson Junco et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study
- (2021) Lei Zha et al. Infectious Diseases and Therapy
- Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge
- (2020) Teresa Gil-Gil et al. Expert Review of Anti-Infective Therapy
- Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone
- (2020) C. Moriceau et al. MEDECINE ET MALADIES INFECTIEUSES
- Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
- (2020) Ahmed M Hamdi et al. Open Forum Infectious Diseases
- Early Experience with Eravacycline for Complicated Infections
- (2020) S Alosaimy et al. Open Forum Infectious Diseases
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
- (2020) Mercedes Delgado-Valverde et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
- (2020) Thomas P Lodise et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tigecycline to treat Stenotrophomonas maltophilia ventilator‐associated pneumonia in a trauma intensive care unit as a result of a drug shortage: A case series
- (2020) Julie E. Farrar et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study
- (2020) Bin Cai et al. Open Forum Infectious Diseases
- Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug resistant Stenotrophomonas maltophilia
- (2020) M Biagi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?
- (2020) Patricia J. Simner et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
- (2020) Gennaro De Pascale et al. Annals of Intensive Care
- Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug resistant Stenotrophomonas maltophilia
- (2020) M Biagi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
- (2020) Stamatis Karakonstantis et al. INFECTION
- Isolation and Characterization of the Novel Bacteriophage AXL3 against Stenotrophomonas maltophilia
- (2020) Jaclyn G. McCutcheon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
- (2019) Ana C Gales et al. Open Forum Infectious Diseases
- Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia
- (2019) Megan D Shah et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models
- (2019) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States
- (2019) Maria F. Mojica et al. mBio
- In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program (2014-2018)
- (2019) Robert K. Flamm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia infections
- (2019) Cara Nys et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model
- (2019) Iris H. Chen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of potential alternative treatment agents for Stenotrophomonas maltophilia non-susceptible to levofloxacin and/or trimethoprim/sulfamethoxazole
- (2019) M Biagi et al. JOURNAL OF CLINICAL MICROBIOLOGY
- In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis
- (2018) Vincent Mathy et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients
- (2018) Eric Farfour et al. Transplant Infectious Disease
- IN VITRO ANTIMICROBIAL ACTIVITY OF CEFTOLOZANE/TAZOBACTAM AGAINST P. AERUGINOSA AND OTHER NON-FERMENTING GRAM-NEGATIVE ORGANISMS IN ADULTS WITH CYSTIC FIBROSIS
- (2018) A. Gramegna et al. Journal of Global Antimicrobial Resistance
- Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis
- (2018) J.-H. Ko et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan
- (2018) Shun-Chung Hsueh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing
- (2018) Sònia Martínez-Servat et al. Frontiers in Microbiology
- Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia : in vitro effects and clinical efficacy in cancer patients
- (2017) Hideki Araoka et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates
- (2017) Karina Calvopiña et al. MOLECULAR MICROBIOLOGY
- I.V. minocycline revisited for infections caused by multidrug-resistant organisms
- (2016) Benjamin Colton et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient
- (2016) Maria F. Mojica et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment ofStenotrophomonas maltophiliainfections
- (2016) Elizabeth Hand et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparison of Monotherapy Versus Combination Therapy for Stenotrophomonas maltophilia Pneumonia Including Trimethoprim-Sulfamethoxazole-Containing and -Sparing Regimens
- (2016) Patrick Lake et al. Open Forum Infectious Diseases
- Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments
- (2016) Chuanqi Wei et al. PLoS One
- Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
- (2016) Antoine Grillon et al. PLoS One
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
- (2015) Ya-Ting Chang et al. Frontiers in Microbiology
- A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused byStenotrophomonas maltophilia
- (2015) Chuanqi Wei et al. Infectious Diseases
- In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012
- (2014) A. Walkty et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia
- (2014) J. W. Betts et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
- (2014) David J. Farrell et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Stenotrophomonas maltophilia:Rare cause of meningitis
- (2014) Cátia Rodrigues Correia et al. PEDIATRICS INTERNATIONAL
- Cotrimoxazole - optimal dosing in the critically ill
- (2014) Glen R Brown Annals of Intensive Care
- Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Infections
- (2013) Yu Lin Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Can Levofloxacin Be a Useful Alternative to Trimethoprim-Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia?
- (2013) Sun Young Cho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Telavancin in Combination with Colistin versus Gram-Negative Bacterial Pathogens
- (2012) Michael Hornsey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia
- (2012) Arianna Pompilio et al. BMC MICROBIOLOGY
- Tigecycline as a therapeutic option inStenotrophomonas maltophiliainfections
- (2012) Yasemin Tezer Tekçe et al. JOURNAL OF CHEMOTHERAPY
- Antimicrobial susceptibility and combination testing of invasiveStenotrophomonas maltophiliaisolates
- (2012) Deirdre Church et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Comparative Activities of Tigecycline and Other Tetracyclines against Nonfermenting Gram-Negative Bacilli, ExcludingAcinetobacterspp.
- (2011) Marisa N. Almuzara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetic and pharmacodynamic evaluation of tigecycline
- (2011) Helen Giamarellou et al. Expert Opinion on Drug Metabolism & Toxicology
- A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan
- (2011) Hsiu Wu et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Treatment of Recurrent Stenotrophomonas maltophilia Ventilator-Associated Pneumonia with Doxycycline and Aerosolized Colistin
- (2010) G. C. Wood et al. ANNALS OF PHARMACOTHERAPY
- Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections
- (2010) D. J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Community-acquired Stenotrophomonas maltophilia infections: a systematic review
- (2009) M. E. Falagas et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Attributable mortality ofStenotrophomonas maltophiliainfections: a systematic review of the literature
- (2009) Matthew E Falagas et al. Future Microbiology
- Stenotrophomonas maltophiliadrug resistance
- (2009) Maria B Sanchez et al. Future Microbiology
- Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
- (2008) N. Petrosillo et al. CLINICAL MICROBIOLOGY AND INFECTION
- Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review
- (2008) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now